The effect of five different administration intervals on the pharmacokinetics (pk) of paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) association regimen

被引：0
|
作者：
Airoldi, M.
Cattel, L.
Passera, R.
Milla, P.
Cerutti, E.
Pedani, F.
Zanon, C.
Crova, A.
机构：
[1] S Giovanni Antica Sede Hosp, Turin, Italy
[2] Univ Torino, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13012
引用
收藏
页数：2
相关论文
共 17 条
  • [1] The impact of five different administration intervals on the pharmacokinetics (PK) of paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) combination
    Cattel, Luigi
    Milla, Paola
    Cerutti, Eleonora
    Pedani, Fulvia
    Airoldi, Mario
    Crova, Alice
    ANNALS OF ONCOLOGY, 2007, 18 : 82 - 83
  • [2] Paclitaxel and pegylated liposomal doxorubicin association: effects of different administration intervals on the pharmacokinetics
    Airoldi, M.
    Cattel, L.
    Milla, P.
    Cerutti, E.
    Pedani, F.
    Crova, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 330 - 331
  • [3] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (CaelyxA®)
    Boers-Sonderen, Marye J.
    van Herpen, Carla M. L.
    van der Graaf, Winette T. A.
    Desar, Ingrid M. E.
    Arens-van der Logt, Mirjam G. W.
    de Beer, Yvo M.
    Ottevanger, Petronella B.
    van Erp, Nielka P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 457 - 463
  • [4] Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)
    Marye J. Boers-Sonderen
    Carla M. L. van Herpen
    Winette T. A. van der Graaf
    Ingrid M. E. Desar
    Mirjam G. W. Arens- van der Logt
    Yvo M. de Beer
    Petronella B. Ottevanger
    Nielka P. van Erp
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 457 - 463
  • [5] Evaluating the effects of bortezomib (Velcade®) on the pharmacokinetics (PK) of pegylated liposomal doxorubicin (Doxil®, PLD)
    La-Beck, Ninh M.
    Walko, Christine M.
    Scoggins, Lakia
    Dees, E. Claire
    Orlowski, Robert Z.
    Wu, Huali
    Amantea, Michael
    Fardin, Mahsa
    Zamboni, William
    CANCER RESEARCH, 2012, 72
  • [6] An open-label study to evaluate dose and cycle dependence of the pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD).
    Gabizon, A.
    Isacson, R.
    Rosengarten, O.
    Tzemach, D.
    Shmeeda, H.
    Sapir, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 82S - 82S
  • [7] Parmacokinetics (PK) of oral vinorelbine (VNR) in association with pegylated liposomal doxorubicin (PLD) in metastatic ovarian carcinoma
    Airoldi, M.
    Cattel, L.
    Milla, P.
    Passera, R.
    Pedani, F.
    Crova, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer
    Kumar, Parag
    Caron, Whitney P.
    Song, Gina
    Gallagher, Katie
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER RESEARCH, 2012, 72
  • [9] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
    Muggia, F. M.
    Boyd, L.
    Liebes, L.
    Downey, A.
    Muller, C.
    Pothuri, B.
    Blank, S.
    Rutledge, T.
    Fishman, D.
    Verschraegen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12